Category: Finance
Closing Bell: Israel’s strikes grip markets; oil and gold spike while the ASX tumbles over 1pc
The ASX closed more than 1pc lower after strong US jobs report and Israeli attack on Iran The Israeli retaliation has gripped risk markets Oil [more…]
Gold Digger: Overvalued or racing towards US$2500/oz? Will the real gold price please stand up?
KEY POINTS: ANZ, Victor Smorgon Group expect gold to trade near US$2500/oz by the end of 2024; Goldman Sachs has a US$2700/oz price target Naysayers [more…]
Godolphin takes full control of its Narraburra project, where rare earths ain’t so rare at all
Remaining 49% of flagship Narraburra project bought from JV partner EX9 for very favourable terms for GRL Considerably strengthens GRL’s landholding which is now includes [more…]
Monsters of Rock: Lithium giant Pilbara Minerals says dividend unlikely, but low costs keep Pilgangoora flying high
Pilbara Minerals says 2024 dividend unlikely despite turn in lithium market Whitehaven Coal bats away questions on costs after mega BHP mine buy Iluka down [more…]
Unicorns Podcast: RecycleSmart, Australia’s ‘Uber for waste’, launches equity crowdfunding campaign
The Unicorns Podcast connects you to some of the best and brightest founders, CEOs, executives, business owners, innovators, entrepreneurs and inspiring leaders who make things [more…]
ASX Small Caps Lunch Wrap: Which US politicians have clearly had a brainfart this week?
Local markets are performing poorly this morning, turning up for work like they’re meant to but sinking like a stone the moment the doors opened [more…]
Resources Top 5: There’s nothing undercooked about these ASX rare earths stocks
Rare earths stocks are having a win as Gina Rinehart amasses equity positions in some of the world’s biggest miners Today’s standout winner on the [more…]
Paradigm makes key submission to US FDA to advance osteoarthritis Phase 3 trial
Paradigm submits key documents to US FDA to advance its pivotal Phase 3 trial of iPPS/Zilosul Biotech also submits a draft of protocol for the [more…]
ASX Health Stocks: Paradigm responds to US FDA, seeks marketing approval from TGA
Paradigm Biopharma submits response to the FDA INOVIQ says its blood test on cancer is highly accurate Paradigm sends response to the US FDA [more…]
Prospecting pays off: DY6 Metals’ new acquisition reveals potential rare earths bonanza
DY6 Metals sampling returns up to 3.22% TREO and 0.75% niobium in Machinga extension licence Licence EL0705 granted in November last year had increased project [more…]
